Analyzing Edge Therapeutics (EDGE) and Kitov Pharmaceuticals (KTOV)
Edge Therapeutics (NASDAQ: EDGE) and Kitov Pharmaceuticals (NASDAQ:KTOV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
Risk and Volatility
Edge Therapeutics has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Kitov Pharmaceuticals has a beta of 2.9, meaning that its share price is 190% more volatile than the S&P 500.
This table compares Edge Therapeutics and Kitov Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Edge Therapeutics and Kitov Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Edge Therapeutics||N/A||N/A||-$38.82 million||($1.56)||-6.03|
|Kitov Pharmaceuticals||N/A||N/A||-$12.12 million||N/A||N/A|
This is a summary of recent recommendations and price targets for Edge Therapeutics and Kitov Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Edge Therapeutics currently has a consensus target price of $25.50, suggesting a potential upside of 171.28%. Kitov Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 352.49%. Given Kitov Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Kitov Pharmaceuticals is more favorable than Edge Therapeutics.
Institutional & Insider Ownership
50.3% of Edge Therapeutics shares are held by institutional investors. Comparatively, 1.1% of Kitov Pharmaceuticals shares are held by institutional investors. 36.2% of Edge Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Kitov Pharmaceuticals beats Edge Therapeutics on 6 of the 8 factors compared between the two stocks.
About Edge Therapeutics
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company’s product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company’s product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).
About Kitov Pharmaceuticals
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.